AU742166C - Progestin therapy with controlled bleeding - Google Patents
Progestin therapy with controlled bleedingInfo
- Publication number
- AU742166C AU742166C AU11914/99A AU1191499A AU742166C AU 742166 C AU742166 C AU 742166C AU 11914/99 A AU11914/99 A AU 11914/99A AU 1191499 A AU1191499 A AU 1191499A AU 742166 C AU742166 C AU 742166C
- Authority
- AU
- Australia
- Prior art keywords
- progestin
- die
- progesterone
- water
- bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 215
- 239000000583 progesterone congener Substances 0.000 title claims description 75
- 230000000740 bleeding effect Effects 0.000 title claims description 47
- 238000002560 therapeutic procedure Methods 0.000 title description 12
- 239000000186 progesterone Substances 0.000 claims description 69
- 229960003387 progesterone Drugs 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 201000000736 Amenorrhea Diseases 0.000 claims description 21
- 206010001928 Amenorrhoea Diseases 0.000 claims description 21
- 231100000540 amenorrhea Toxicity 0.000 claims description 21
- 229940011871 estrogen Drugs 0.000 claims description 16
- 239000000262 estrogen Substances 0.000 claims description 16
- 239000000227 bioadhesive Substances 0.000 claims description 14
- 206010047998 Withdrawal bleed Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 238000012377 drug delivery Methods 0.000 claims description 8
- 210000004696 endometrium Anatomy 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 6
- 206010051909 Endometrial atrophy Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 3
- 229950005134 polycarbophil Drugs 0.000 claims 3
- 208000034423 Delivery Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000009677 vaginal delivery Effects 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 description 47
- 208000034158 bleeding Diseases 0.000 description 47
- 239000000499 gel Substances 0.000 description 33
- 229940000593 crinone Drugs 0.000 description 24
- 238000011282 treatment Methods 0.000 description 21
- 238000002657 hormone replacement therapy Methods 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 230000002354 daily effect Effects 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000002357 endometrial effect Effects 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 8
- 230000009245 menopause Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000035587 bioadhesion Effects 0.000 description 5
- 229940074117 estraderm Drugs 0.000 description 5
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000009164 estrogen replacement therapy Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940035811 conjugated estrogen Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010049513 Luteal phase deficiency Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- -1 glucocorticoids Chemical class 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- AHAREKHAZNPPMI-UHFFFAOYSA-N hexa-1,3-diene Chemical compound CCC=CC=C AHAREKHAZNPPMI-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011452 sequencing regimen Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6348597P | 1997-10-21 | 1997-10-21 | |
| US60/063485 | 1997-10-21 | ||
| US09/170326 | 1998-10-13 | ||
| US09/170,326 US6306914B1 (en) | 1997-10-21 | 1998-10-13 | Progestin therapy for maintaining amenorrhea |
| PCT/US1998/022169 WO1999020282A1 (en) | 1997-10-21 | 1998-10-21 | Progestin therapy with controlled bleeding |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU1191499A AU1191499A (en) | 1999-05-10 |
| AU742166B2 AU742166B2 (en) | 2001-12-20 |
| AU742166C true AU742166C (en) | 2005-07-14 |
Family
ID=26743461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU11914/99A Ceased AU742166C (en) | 1997-10-21 | 1998-10-21 | Progestin therapy with controlled bleeding |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6306914B1 (enExample) |
| EP (1) | EP1032399A1 (enExample) |
| JP (1) | JP2003535015A (enExample) |
| KR (1) | KR100581308B1 (enExample) |
| CN (1) | CN1147301C (enExample) |
| AR (1) | AR013981A1 (enExample) |
| AU (1) | AU742166C (enExample) |
| BR (1) | BR9813262A (enExample) |
| CA (2) | CA2307615A1 (enExample) |
| HU (1) | HUP0004133A3 (enExample) |
| IL (1) | IL135742A (enExample) |
| MX (1) | MXPA00003972A (enExample) |
| MY (1) | MY121743A (enExample) |
| NO (1) | NO326856B1 (enExample) |
| NZ (1) | NZ504066A (enExample) |
| PE (1) | PE121799A1 (enExample) |
| RO (1) | RO121319B1 (enExample) |
| RU (2) | RU2261099C2 (enExample) |
| WO (1) | WO1999020282A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| US8425892B2 (en) * | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
| ES2561491T3 (es) * | 2001-12-05 | 2016-02-26 | Teva Women's Health, Inc. | Anticonceptivos orales para prevenir el embarazo |
| CA2496618A1 (en) * | 2002-05-23 | 2003-12-04 | Michael Holick | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
| AU2003297534A1 (en) * | 2002-12-24 | 2004-07-22 | Ovion, Inc. | Contraceptive device and delivery system |
| CA2524474A1 (en) * | 2003-05-02 | 2004-11-18 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
| SI1635843T1 (sl) * | 2003-06-25 | 2009-06-30 | Bayer Schering Pharma Ag | Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo |
| JP2007534622A (ja) * | 2003-07-16 | 2007-11-29 | デュラメド ファーマシューティカルズ インコーポレーティッド | 連続的エストロゲン投与での避妊薬療法を利用するホルモン処置の方法 |
| EP1761231A1 (en) * | 2004-06-07 | 2007-03-14 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| JP2009521533A (ja) * | 2005-12-27 | 2009-06-04 | デュラメド ファーマシューティカルズ インコーポレーティッド | 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法 |
| CA2637608A1 (en) * | 2006-01-20 | 2007-07-26 | Pear Tree Pharmaceuticals, Inc. | Method of treating atrophic vaginitis |
| US8235047B2 (en) | 2006-03-30 | 2012-08-07 | Conceptus, Inc. | Methods and devices for deployment into a lumen |
| CA2654152A1 (en) * | 2006-06-02 | 2007-12-13 | Pear Tree Women's Health Care | Method of treating atrophic vaginitis |
| GB0616444D0 (en) * | 2006-08-18 | 2006-09-27 | Reckitt Benckiser Nv | Detergent composition |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| MX337634B (es) | 2008-02-04 | 2016-03-14 | Teva Womens Health Inc | Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos. |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| RU2697369C1 (ru) * | 2018-12-21 | 2019-08-13 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской | Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN113288865B (zh) * | 2021-06-28 | 2022-03-08 | 浙江仙琚制药股份有限公司 | 一种黄体酮阴道凝胶剂的制备方法 |
| CN114983929A (zh) * | 2022-05-16 | 2022-09-02 | 安徽万邦医药科技股份有限公司 | 一种稳定的黄体酮缓释凝胶及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995007699A1 (en) * | 1993-09-15 | 1995-03-23 | Columbia Laboratories, Inc. | Novel method of progesterone delivery and affect thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
| USD345211S (en) | 1992-04-06 | 1994-03-15 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
| USD375352S (en) | 1994-03-14 | 1996-11-05 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
-
1998
- 1998-10-13 US US09/170,326 patent/US6306914B1/en not_active Expired - Fee Related
- 1998-10-21 MX MXPA00003972A patent/MXPA00003972A/es not_active IP Right Cessation
- 1998-10-21 HU HU0004133A patent/HUP0004133A3/hu unknown
- 1998-10-21 AU AU11914/99A patent/AU742166C/en not_active Ceased
- 1998-10-21 CN CNB988123894A patent/CN1147301C/zh not_active Expired - Fee Related
- 1998-10-21 RU RU2000112650/14A patent/RU2261099C2/ru not_active IP Right Cessation
- 1998-10-21 NZ NZ504066A patent/NZ504066A/xx unknown
- 1998-10-21 JP JP2000516679A patent/JP2003535015A/ja active Pending
- 1998-10-21 BR BR9813262-8A patent/BR9813262A/pt not_active Application Discontinuation
- 1998-10-21 EP EP98955011A patent/EP1032399A1/en not_active Withdrawn
- 1998-10-21 PE PE1998000990A patent/PE121799A1/es not_active Application Discontinuation
- 1998-10-21 CA CA002307615A patent/CA2307615A1/en not_active Abandoned
- 1998-10-21 WO PCT/US1998/022169 patent/WO1999020282A1/en not_active Ceased
- 1998-10-21 KR KR1020007004288A patent/KR100581308B1/ko not_active Expired - Fee Related
- 1998-10-21 RO ROA200000428A patent/RO121319B1/ro unknown
- 1998-10-21 IL IL13574298A patent/IL135742A/en not_active IP Right Cessation
- 1998-10-21 CA CA002649671A patent/CA2649671A1/en not_active Abandoned
- 1998-10-21 MY MYPI98004790A patent/MY121743A/en unknown
- 1998-10-22 AR ARP980105256A patent/AR013981A1/es unknown
-
2000
- 2000-04-19 NO NO20002084A patent/NO326856B1/no not_active IP Right Cessation
- 2000-10-17 US US09/833,259 patent/US6593317B1/en not_active Expired - Fee Related
-
2001
- 2001-04-03 US US09/825,569 patent/US20010031747A1/en active Pending
-
2005
- 2005-01-21 RU RU2005101612/14A patent/RU2330667C2/ru not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995007699A1 (en) * | 1993-09-15 | 1995-03-23 | Columbia Laboratories, Inc. | Novel method of progesterone delivery and affect thereof |
Non-Patent Citations (1)
| Title |
|---|
| MATURITAS, V27 NO. SUPPL. F168, 1997, P95-96, XP 002094217 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100581308B1 (ko) | 2006-05-22 |
| IL135742A0 (en) | 2001-05-20 |
| AR013981A1 (es) | 2001-01-31 |
| CA2307615A1 (en) | 1999-04-29 |
| MY121743A (en) | 2006-02-28 |
| RU2005101612A (ru) | 2006-07-10 |
| AU1191499A (en) | 1999-05-10 |
| US6306914B1 (en) | 2001-10-23 |
| NO326856B1 (no) | 2009-03-02 |
| AU742166B2 (en) | 2001-12-20 |
| EP1032399A1 (en) | 2000-09-06 |
| PE121799A1 (es) | 1999-12-17 |
| BR9813262A (pt) | 2000-08-22 |
| US20010031747A1 (en) | 2001-10-18 |
| RO121319B1 (ro) | 2007-03-30 |
| NZ504066A (en) | 2002-11-26 |
| CN1147301C (zh) | 2004-04-28 |
| RU2330667C2 (ru) | 2008-08-10 |
| WO1999020282A1 (en) | 1999-04-29 |
| RU2261099C2 (ru) | 2005-09-27 |
| NO20002084L (no) | 2000-06-21 |
| JP2003535015A (ja) | 2003-11-25 |
| US6593317B1 (en) | 2003-07-15 |
| IL135742A (en) | 2004-09-27 |
| KR20010031299A (ko) | 2001-04-16 |
| HUP0004133A3 (en) | 2001-09-28 |
| NO20002084D0 (no) | 2000-04-19 |
| MXPA00003972A (es) | 2004-04-21 |
| HUP0004133A2 (hu) | 2001-05-28 |
| CA2649671A1 (en) | 1999-04-29 |
| CN1282250A (zh) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU742166C (en) | Progestin therapy with controlled bleeding | |
| US5543150A (en) | Method of progesterone delivery and affect thereof | |
| AU715740C (en) | Progesterone for treating or reducing ischemia | |
| CA2782075C (en) | Nestorone/estradiol transdermal gel | |
| Murray | Natural progesterone: what role in women’s health care | |
| BG106442A (bg) | Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания | |
| AU689133C (en) | Novel method of progesterone delivery and affect thereof | |
| UA79421C2 (en) | Progestin therapy with regular menstrual bleeding | |
| US20070178139A1 (en) | Vaginally administratable progesterone-containing tablets and method for preparing same | |
| Watkinson | The pharmacokinetics of drug delivery systems in hormone replacement therapy | |
| HK1121685A (en) | Hormonal composition consisting of an estrogen compound and of a progestational compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040419 |